Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
360.03B
Market cap360.03B
Price-Earnings ratio
117.79
Price-Earnings ratio117.79
Dividend yield
2.31%
Dividend yield2.31%
Average volume
9.29M
Average volume9.29M
High today
$147.80
High today$147.80
Low today
$144.64
Low today$144.64
Open price
$146.96
Open price$146.96
Volume
11.23M
Volume11.23M
52 Week high
$156.92
52 Week high$156.92
52 Week low
$82.01
52 Week low$82.01

Stock Snapshot

With a market cap of 360.03B, Merck(MRK) trades at $145.31. The stock has a price-to-earnings ratio of 117.79 and currently yields dividends of 2.31%.

On 2026-10-17, Merck(MRK) stock traded between a low of $144.64 and a high of $147.80. Shares are currently priced at $145.31, which is +0.5% above the low and -1.7% below the high.

Merck(MRK) shares are trading with a volume of 11.23M, against a daily average of 9.29M.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

During the past year, Merck(MRK) stock moved between $82.01 at its lowest and $156.92 at its peak.

MRK News

Simply Wall St 17h
How Investors Are Reacting To Merck Phase 3 Skin Cancer Data

Merck announced that Paul J. Diaz, a healthcare investor and former CEO of Myriad Genetics and Kindred Healthcare, joined its board in November 2026. At the sam...

How Investors Are Reacting To Merck Phase 3 Skin Cancer Data
24/7 Wall St. 23h
Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Investing Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know Bristol Myers Squibb has raised its dividend for 17 straight y...

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Simply Wall St 2d
Merck Adds A Board Veteran, Is It Still 5% Below Fair Value?

Merck (MRK) is back in focus after the company said Paul J. Diaz will join its board on November 1, 2026. The appointment adds deep health care and investment e...

Merck Adds A Board Veteran, Is It Still 5% Below Fair Value?

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More MRK News

MarketWatch 2d
Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Biopharma stocks like AbbVie and Eli Lilly are trading at or near all-time highs, in the latest signal that investors are seeking out the steady gains that come...

Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
24/7 Wall St. 2d
AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow

Investing AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow Amgen and Merck both yield around 2.3% and have surged this year, but one of the...

AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
Zacks 2d
Here is What to Know Beyond Why Merck & Co., Inc. is a Trending Stock

Merck (MRK Quick QuoteMRK - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the...

Here is What to Know Beyond Why Merck & Co., Inc. is a Trending Stock
TIME 2d
Merck Lipfendra: The Best Inventions of 2026 - Time Magazine

...

Merck Lipfendra: The Best Inventions of 2026 - Time Magazine
CNBC 3d
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

Key Points Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowle...

Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
TipRanks 4d
Merck appoints Paul Diaz to its board of directors

An update from Merck & Company ( (MRK) ) is now available. On Oct. 13, 2026, Merck & Co., Inc. announced that Paul J. Diaz, managing partner at private investm...

Simply Wall St 4d
Merck Stock Could Be A Bargain As Its 120% Run Continues

has had a powerful multiyear run, and with oncology news still coming thick and fast, the real issue for you now is whether the current share price lines up wit...

Merck Stock Could Be A Bargain As Its 120% Run Continues

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.